Dear Sir or Madam,

The Else Kröner-Fresenius Foundation would like to invite you to the 4th Workshop for Translational Research on **May 7, 2020 in Frankfurt/Main**. You will find the official program attached to this invitation.
During the workshop, distinguished experts will discuss the important challenge of:

“How to Improve Translational Medicine”

They will present possible solutions to increase the chances of biomedical products reaching the market and benefiting the patients.

Come and join us in Frankfurt to discuss the possibilities for empowering translational medicine, and learn about a variety of tools to support and finance your translational research project on its way to clinical application.

Attending the workshop is free of charge; however, you will need to register officially by using the following e-mail address: translatorik@ekfs.de

The limited seats will be allocated according to the time of registration (first come, first served).

We look forward to welcoming you in May 2020!

Best regards,

Martin Zörnig

If you plan to arrive the day before the workshop, i.e. May 6, 2020, you are entitled to book a room in the Hotel Novotel Frankfurt City at a reduced price of € 91 for an overnight stay from May 6 to 7, 2020.

Please use the following phone number +49 69 79303 905 or e-mail address H1049-RE2@accor.com and mention the code “EKFS Workshop Translatorik” for reservation.

A (very) limited number of parking spaces will be available on-site. For public transportation, the following stops are located close to the location (guest house Frauenlobstraße):

- Frankfurt Main West: IC, ICE, RB, RE, S5, S6 – 23-minute walk to location
- Bockenheimer Warte: U4, U6, U7, tram no. 16 – 13-minute walk to location
- Leipziger Straße: U6, U7 – 12-minute walk to location
4th EKFS Workshop of Translational Research

May 7, 2020

9 a.m. (local time)

Guest house Frauenlobstraße of the Goethe University of Frankfurt
Frauenlobstraße 1, 60487 Frankfurt am Main, Germany

Program

09:30 – 09:45 Professor Martin Zörnig (EKFS): Welcome and introduction of the EKFS funding line for translational research

09:45 – 10:15 Dr. Daniel Merk (University of Frankfurt): “Dual FXR/sEH modulators – from basic medicinal chemistry to a preclinical candidate,” an example of a project supported by the EKFS funding line for translational research

10:15 – 11:00 Dr. Ansgar Santel (Technology Development Manager at Ascenion): “Dos and don'ts when applying for translational funding”

11:00 – 11:30 Coffee break

11:30 – 12:15 Dr. Jeff Skinner (Executive Director of the Institute of Innovation and Entrepreneurship, London Business School): “The use and abuse of proof-of-concept funds”

12:15 – 12:45 Dr. Martina Schüßler-Lenz (Paul-Ehrlich-Institute, Federal Institute for Vaccines and Biomedicines, and Chair of EMA Committee for Advanced Therapies): “From bench to bedside – an overview of medicinal product development”

12:45 – 13:45 Lunch

13:45 – 14:30 Professor Aled Edwards (University of Toronto, Director of the Structural Genomics Consortium, Director of M4K Pharma): “Open drug discovery – a path to affordably priced new medicines”

14:30 – 15:15 Professor Jochen Maas (General Manager of R & D at Sanofi-Aventis Deutschland GmbH): “From bench to bedside and from bedside to bench – how translational and individualized medicine change medical paradigms”

15:15 – 15:45 Coffee break

15:45 – 16:30 Dr. Lena Krzyzak (Senior Investment Manager at High-Tech Gründerfonds Management GmbH): “From scientific discovery to building a start-up company – fostering translation from bench to bedside: insights into High-Tech Gründerfonds’ life science portfolio”

16:30 – 16:45 Dr. Jörg Fregien (Managing Director of Life Science Incubator): “The Life Science Incubator (LSI) – from idea to market”

16:45 – 17:15 Dr. Jörn Erselius (Managing Director of Max-Planck-Innovation GmbH): “Helping basic science into application”

17:15 – 17:30 Dr. Martin Raditsch (Managing Director of INNOVECTIS): “The CaRMA fund – a new way of derisking life science investments”

17:30 Professor Martin Zörnig: Closing remarks